Skip to main content

Cata-Kor Expands Wellness Portfolio With Science-Focused NAD Support Formulation

Cata-Kor announced an expansion of its wellness portfolio with an NMN-based formulation positioned around NAD⁺ support and third-party testing standards.

-- Cata-Kor, a U.S. supplement brand focused on NAD-related formulations, is expanding its lineup with a nicotinamide mononucleotide product, the Cata-Kor NMN Supplement 1000mg – 4-in-1 NAD Supplement with Querceti, TMG, and Resveratrol. The company said the release reflects a longer-term effort to build a more defined presence in the NAD Supplement category by emphasizing formulation design, sourcing transparency and routine quality controls.

The product is built around NMN, positioned by the company as a direct NAD precursor. Cata-Kor said the formulation also includes Quercetin, TMG and Resveratrol, an ingredient combination used in some nmn supplement products intended to support cellular energy and mitochondrial function as part of an overall wellness routine.

“This is a focused addition to the portfolio, built around NMN and a complementary ingredient set that many consumers already associate with NAD support,” a Cata-Kor spokesperson said. “The goal was to deliver a straightforward NMN supplement with a clear label, consistent manufacturing controls and a quality process that consumers can understand.”

Cata-Kor said each batch is third-party tested in the United States for heavy metal safety through accredited laboratories, with a certificate of analysis available upon request. The company also said the product is manufactured and packaged in the United States using globally sourced ingredients.

“As the NMN category continues to evolve, the company is prioritizing a product that fits a science-minded positioning and can scale with future portfolio planning,” the spokesperson said. “This release is part of a broader roadmap to expand offerings in a disciplined way, without overpromising results.”

The product is available through Amazon at: https://www.amazon.com/dp/B0FWGXBT3C?maas=maas_adg_1D910B8912D89E61FBEF000087B67596_afap_abs&ref_=aa_maas&tag=maas&th=1

About Cata-Kor

Cata-Kor is a U.S.-based wellness supplement brand that develops products positioned around NAD-related formulations and broader cellular wellness support. The company’s portfolio includes NMN and related offerings designed for adult daily routines.

Cata-Kor states that its products are manufactured and packaged in the United States using globally sourced ingredients and supported by third-party testing protocols. The company’s longer-term strategy is centered on portfolio expansion guided by formulation clarity, sourcing standards and quality documentation.

Disclaimer:

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Contact Info:
Name: Mariya
Email: Send Email
Organization: Cata-Kor
Website: https://www.amazon.com/dp/B0FWGXBT3C?maas=maas_adg_1D910B8912D89E61FBEF000087B67596_afap_abs&ref_=aa_maas&tag=maas&th=1

Release ID: 89179649

Should you identify any discrepancies, concerns, or inaccuracies in the content provided in this press release or require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team is committed to addressing your concerns within 8 hours by taking necessary actions to resolve identified issues diligently or guiding you through the necessary steps for removal. Our dedication lies in providing accurate and reliable information.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.50
-4.32 (-1.87%)
AAPL  271.01
-0.85 (-0.31%)
AMD  223.47
+9.31 (4.35%)
BAC  55.95
+0.95 (1.73%)
GOOG  315.32
+1.52 (0.48%)
META  650.41
-9.68 (-1.47%)
MSFT  472.94
-10.68 (-2.21%)
NVDA  188.85
+2.35 (1.26%)
ORCL  195.71
+0.80 (0.41%)
TSLA  438.07
-11.65 (-2.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.